Viyash Scientific Gets Italian Approval for BioForLife Acquisition, Deal Expected Within Two Months
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, has received the required regulatory approval from Italian authorities for its proposed acquisition of 100% of BioForLife Italia S.r.l., marking an important step towards completing the transaction.
The company informed the stock exchanges on September 8, 2026, that the requisite approval under the applicable Italian FDI/Golden Power regulations has been received.
Following the approval, Viyash Scientific now expects the transaction to be completed within two months, subject to customary closing formalities and other closing conditions.
Viyash Scientific-BioForLife acquisition: What happened?
Viyash Scientific had previously disclosed its plan to acquire the entire shareholding of BioForLife Italia S.r.l., Milan, Italy.
The acquisition is being undertaken through Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific.
The company has now received the necessary approval from the relevant Italian authorities under the applicable FDI/Golden Power framework.
This removes an important regulatory condition associated with the proposed transaction.
Deal completion timeline revised
Although regulatory approval has been received, the acquisition has not yet closed.
Viyash Scientific said that, considering the remaining customary closing formalities and closing conditions, the expected completion timeline has been revised.
The transaction is now expected to be completed within two months from September 8, 2026.
Therefore, investors can potentially expect further disclosure regarding completion of the acquisition during the coming months.
Why the Italian approval matters
The Italian FDI/Golden Power approval represents an important milestone because regulatory clearance was one of the conditions required for the transaction to proceed.
With the approval now received, the acquisition moves closer to completion.
However, investors should distinguish between regulatory approval and actual completion of the acquisition.
The company still needs to complete the remaining customary closing formalities and satisfy the applicable closing conditions.
What is BioForLife Italia?
BioForLife Italia S.r.l. is based in Milan, Italy, and is the target company in Viyash Scientific’s proposed acquisition.
The transaction is being pursued through Alivira Animal Health Limited, which operates within Viyash’s animal-health business.
The acquisition is therefore strategically relevant to Viyash Scientific’s international animal-health operations.
Viyash Scientific stock: Why the company is in focus
Viyash Scientific is in focus after receiving Italian regulatory approval for its proposed acquisition of BioForLife Italia.
The important developments for investors are:
- Italian FDI/Golden Power approval has been received.
- The proposed acquisition covers 100% of BioForLife Italia S.r.l.
- The acquisition is being undertaken through Alivira Animal Health Limited, Ireland.
- Alivira is a step-down wholly owned subsidiary of Viyash Scientific.
- The transaction is now expected to be completed within two months.
- Remaining customary closing formalities and closing conditions still need to be completed.
- Other material terms and conditions of the previously disclosed transaction remain unchanged.
Strategic significance for Viyash Scientific
The proposed acquisition is relevant to Viyash Scientific’s strategy of expanding its international animal-health business.
The company operates in the pharmaceutical and animal-health space, and acquisitions can potentially help expand its geographic presence, product portfolio and customer base.
The latest regulatory approval reduces one of the key hurdles to completing the BioForLife transaction.
The eventual impact on Viyash Scientific’s financial performance, however, will depend on the successful completion of the acquisition and the subsequent contribution from the acquired business.
What investors should watch next
The next major milestone is likely to be the completion of the acquisition.
Investors should watch for:
- Final closing of the transaction
- Completion of remaining conditions
- Integration of BioForLife Italia
- Financial contribution from the acquired business
- Any changes to Viyash’s animal-health portfolio
- Management commentary on the acquisition and future strategy
Until the transaction closes, the financial impact should not be treated as fully reflected in Viyash Scientific’s operating performance.
Investor takeaway
The receipt of Italian FDI/Golden Power approval is a positive milestone for Viyash Scientific’s proposed BioForLife Italia acquisition.
The transaction has moved closer to completion, with the company now expecting the deal to close within two months, subject to the remaining formalities and conditions.
For investors, the next important development will be the actual completion of the acquisition and any subsequent disclosure regarding its strategic and financial impact.
This announcement is therefore more significant than a routine compliance filing because it represents progress on a previously announced acquisition and removes an important regulatory hurdle.
Disclaimer
This article is for informational and educational purposes only and should not be considered investment advice. Investors should independently evaluate Viyash Scientific’s financial performance, valuation, acquisition terms, risks and future prospects before making investment decisions.